Printed From BioPortfolio.com
Positive phase III results for Pfizer’s trastuzumab biosimilar
04:29 EDT 22 Sep 2017 | Generics and Biosimilars Initiative
Pharma giant Pfizer announced on 10 September 2017 positive results from the pivotal phase III study of its candidate trastuzumab biosimilar. Pfizer says that ‘data from the REFLECTIONS B327-02 study demonstrates equivalence in objective response rate (ORR) for patients with HER2-positive metastatic breast cancer’.
Original Article: Positive phase III results for Pfizer’s trastuzumab biosimilar
